Translational Research and Evolving Alcoholic hepatitis Treatment (TREAT-IU)
转化研究和不断发展的酒精性肝炎治疗 (TREAT-IU)
基本信息
- 批准号:8921359
- 负责人:
- 金额:$ 6.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-15 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcidsAcute Alcoholic HepatitisAddressAdrenal Cortex HormonesAdultAffectAgeAgonistAlcohol consumptionAlcoholic HepatitisAlcoholic Liver DiseasesAlcoholic beverage heavy drinkerAlcoholsAntibodiesBackBacterial TranslocationBile AcidsCYP2E1 geneCaspase InhibitorCellsClinicClinicalDrug KineticsEnrollmentFatty LiverFecesFibroblast Growth FactorFoundationsFunctional disorderGenderGenomic DNAGlossaryGoalsHealthHeavy DrinkingHepaticHepatocyteHistologicHomeostasisHospitalizationHumanImmune responseImpairmentIncidenceIndianaIndividualInflammationInjury to LiverKupffer CellsLaboratoriesLength of StayLipopolysaccharidesLiverLiver diseasesMetabolismModelingMononuclearMorbidity - disease rateMultiple AbnormalitiesNatural ImmunityNuclear ReceptorsObservational StudyOralOral cavityOxidative StressPathogenesisPathway interactionsPatient CarePatientsPeripheralPermeabilityPlacebo ControlPlacebosPlasmaPublic HealthQuestionnairesRaceRandomizedRandomized Controlled TrialsRecording of previous eventsResearch PersonnelSafetySample SizeSamplingSerious Adverse EventSeveritiesSignal TransductionStagingTestingTherapeutic StudiesTimeTissuesTranslational ResearchUniversitiesUrineVirginiaalcohol researchbile saltscase controlcohortcytokinedrinkingeffective therapymeetingsmembermortalitynamed groupnovelnovel strategiespatient oriented researchprospectivereceptorrepositoryresponsetherapy developmenttranslational study
项目摘要
DESCRIPTION (provided by applicant): In response to the RFA-AA-12-007, Indiana University (IU), Mayo Clinic (Mayo), and Virginia Commonwealth University (VCU) have formed a consortium "Translational Research and Evolving Alcoholic Hepatitis Treatments"(TREAT). Central hypotheses of this application are: (a) a large cohort of patients with well-characterized acute alcoholic hepatitis (AH) and matched controls greatly enhances our ability to conduct translational studies in humans to better understand its pathogenesis and to develop novel treatments, and (b) alcohol-induced impairment of signaling via bile salt receptors impairs gut integrity, permits activation of Kupffer cells, enhances oxidative stress in the liver, stimulates fatty liver, and sensitizes hepatocytes to cytokine-induced necroapoptosis, and that these abnormalities can be reversed with the FXR agonist, obeticholic acid (OCA). We will address these hypotheses by conducting the following patient- oriented studies. Specific Aim 1: To conduct a prospective multicenter observational study of patients with well-characterized AH and suitable controls that serves as the foundation for conducting novel mechanistic and therapeutic studies. A robust central bio-repository of serum/plasma, peripheral mononuclear cells, genomic DNA, urine, stool samples, and liver tissue (where available) will be developed from both cases and controls. Specific Aim 2: To test the hypothesis that alcohol-induced impairment of signaling via farnesoid X receptor (FXR, the bile salt nuclear receptor) interrupts normal bile salt homeostasis, and that this will be reversed with an FXR agonist, obeticholic acids (OCA). A secondary hypothesis is that altered FXR signaling impairs gut integrity, promotes activation of the innate immune response, enhances hepatic oxidative stress, and sensitizes hepatocytes to cytokine-induced necroapoptosis. . To address these hypotheses, we will conduct a study of bile salt metabolism and effects of OCA in heavy drinkers without liver disease (n=15), moderate drinkers (n=15), and non-drinkers (n=15). Specific Aim 3: To test the hypothesis that FXR agonists are effective in treating AH by correcting multiple abnormalities implicated in its pathogenesis. We will test this hypothesis by conducting a proof-of-concept multicenter, placebo-controlled randomized controlled trial of OCA in patients with moderately severe AH. Sixty adults with AH of moderate severity will be randomized to receive either obeticholic acid (10 mg once daily by mouth) or placebo for 4 weeks. Primary efficacy end point is change in MELD score at 4 weeks [5] and the primary safety end point is the incidence of serious adverse events (SAE) at 4 weeks. Specific aim 4: To participate in the two other proof-of-concept studies proposed by the other two members of the TREAT consortium.
描述(由申请人提供):为了响应 RFA-AA-12-007,印第安纳大学 (IU)、梅奥诊所 (Mayo) 和弗吉尼亚联邦大学 (VCU) 成立了一个“转化研究和不断发展的酒精性肝炎治疗”(TREAT) 联盟。该应用的中心假设是:(a) 一大群患有明确特征的急性酒精性肝炎 (AH) 的患者和匹配的对照极大地增强了我们在人类中进行转化研究的能力,以更好地了解其发病机制并开发新的治疗方法,以及 (b) 酒精引起的胆汁盐受体信号传导损伤会损害肠道完整性,允许库普弗细胞激活,增强肠道中的氧化应激 FXR 激动剂奥贝胆酸 (OCA) 可以逆转这些异常。我们将通过进行以下以患者为导向的研究来解决这些假设。具体目标 1:对具有明确特征的 AH 患者和合适的对照进行前瞻性多中心观察研究,作为开展新机制和治疗研究的基础。血清/血浆、外周单核细胞、基因组 DNA、尿液、粪便样本和肝组织(如果有)的强大中央生物存储库将从病例和对照中开发出来。具体目标 2:检验以下假设:酒精引起的法尼醇 X 受体(FXR,胆汁盐核受体)信号传导受损会中断正常的胆汁盐稳态,而 FXR 激动剂奥贝胆酸 (OCA) 可以逆转这种情况。第二个假设是,改变的 FXR 信号传导会损害肠道完整性,促进先天免疫反应的激活,增强肝脏氧化应激,并使肝细胞对细胞因子诱导的坏死性凋亡敏感。 。为了解决这些假设,我们将在无肝病的重度饮酒者 (n=15)、中度饮酒者 (n=15) 和不饮酒者 (n=15) 中开展胆汁盐代谢和 OCA 影响的研究。具体目标 3:检验 FXR 激动剂通过纠正 AH 发病机制中涉及的多种异常而有效治疗 AH 的假设。我们将通过在中度严重 AH 患者中进行 OCA 多中心、安慰剂对照随机对照试验来验证这一假设。 60 名患有中度 AH 的成人将随机接受奥贝胆酸(10 毫克,每天口服一次)或安慰剂,为期 4 周。主要疗效终点是 4 周时 MELD 评分的变化 [5],主要安全终点是 4 周时严重不良事件 (SAE) 的发生率。具体目标 4:参与 TREAT 联盟其他两名成员提出的另外两项概念验证研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NAGA P CHALASANI其他文献
NAGA P CHALASANI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NAGA P CHALASANI', 18)}}的其他基金
Ancillary Studies of NAFLD and NASH in HIV infected Adults
HIV 感染成人 NAFLD 和 NASH 的辅助研究
- 批准号:
9754980 - 财政年份:2020
- 资助金额:
$ 6.68万 - 项目类别:
Ancillary Studies of NAFLD and NASH in HIV infected Adults
HIV 感染成人 NAFLD 和 NASH 的辅助研究
- 批准号:
10371070 - 财政年份:2020
- 资助金额:
$ 6.68万 - 项目类别:
Ancillary Studies of NAFLD and NASH in HIV infected Adults
HIV 感染成人 NAFLD 和 NASH 的辅助研究
- 批准号:
10555206 - 财政年份:2020
- 资助金额:
$ 6.68万 - 项目类别:
Translational Research and Evolving Alcoholic hepatitis Treatment (TREAT-IU)
转化研究和不断发展的酒精性肝炎治疗 (TREAT-IU)
- 批准号:
8427105 - 财政年份:2012
- 资助金额:
$ 6.68万 - 项目类别:
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 2/9
酒精性肝炎临床和转化网络后期临床试验和观察研究 2/9
- 批准号:
10440312 - 财政年份:2012
- 资助金额:
$ 6.68万 - 项目类别:
Translational Research and Evolving Alcoholic hepatitis Treatment (TREAT-IU)
转化研究和不断发展的酒精性肝炎治疗 (TREAT-IU)
- 批准号:
8695260 - 财政年份:2012
- 资助金额:
$ 6.68万 - 项目类别:
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 2/9
酒精性肝炎临床和转化网络后期临床试验和观察研究 2/9
- 批准号:
10203744 - 财政年份:2012
- 资助金额:
$ 6.68万 - 项目类别:
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 2/9
酒精性肝炎临床和转化网络后期临床试验和观察研究 2/9
- 批准号:
9988081 - 财政年份:2012
- 资助金额:
$ 6.68万 - 项目类别:
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 2/9
酒精性肝炎临床和转化网络后期临床试验和观察研究 2/9
- 批准号:
9589466 - 财政年份:2012
- 资助金额:
$ 6.68万 - 项目类别:
Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 2/9
酒精性肝炎临床和转化网络后期临床试验和观察研究 2/9
- 批准号:
9752395 - 财政年份:2012
- 资助金额:
$ 6.68万 - 项目类别:
相似海外基金
A hepatocyte-specific R-spondin mimetic bispecific fusion protein to stimulate hepatocyte regeneration in patients with acute alcoholic hepatitis
一种肝细胞特异性 R-spondin 模拟双特异性融合蛋白,可刺激急性酒精性肝炎患者的肝细胞再生
- 批准号:
10269934 - 财政年份:2020
- 资助金额:
$ 6.68万 - 项目类别:
A hepatocyte-specific R-spondin mimetic bispecific fusion protein to stimulate hepatocyte regeneration in patients with acute alcoholic hepatitis
一种肝细胞特异性 R-spondin 模拟双特异性融合蛋白,可刺激急性酒精性肝炎患者的肝细胞再生
- 批准号:
10488068 - 财政年份:2020
- 资助金额:
$ 6.68万 - 项目类别:
A hepatocyte-specific R-spondin mimetic bispecific fusion protein to stimulate hepatocyte regeneration in patients with acute alcoholic hepatitis
一种肝细胞特异性 R-spondin 模拟双特异性融合蛋白,可刺激急性酒精性肝炎患者的肝细胞再生
- 批准号:
10707988 - 财政年份:2020
- 资助金额:
$ 6.68万 - 项目类别:
THALIDOMIDE IN PATIENTS WITH ACUTE ALCOHOLIC HEPATITIS
沙利度胺用于急性酒精性肝炎患者
- 批准号:
7201331 - 财政年份:2005
- 资助金额:
$ 6.68万 - 项目类别:
THALIDOMIDE IN PATIENTS WITH ACUTE ALCOHOLIC HEPATITIS
沙利度胺用于急性酒精性肝炎患者
- 批准号:
7040813 - 财政年份:2004
- 资助金额:
$ 6.68万 - 项目类别:
STUDIES OF AMINO ACID INFUSION IN ACUTE ALCOHOLIC HEPATITIS
氨基酸输注治疗急性酒精性肝炎的研究
- 批准号:
4697975 - 财政年份:
- 资助金额:
$ 6.68万 - 项目类别:














{{item.name}}会员




